Brief: Anpac Bio Reports Qtrly Loss Per Share RMB 2.43
27/05/2021 11:58
May 27 (Reuters) - AnPac Bio-Medical Science Co Ltd
ANPC.O :
* ANPAC BIO REPORTS STRONG FIRST QUARTER IN 2021, WITH
137.2%
INCREASE IN REVENUE AND RECORD NUMBER OF COMMERCIAL TESTS
COMPLETED
* Q1 REVENUE ROSE 137.2 PERCENT TO RMB 2.2 MILLION
* QTRLY LOSS PER SHARE RMB 2.43
Source text for Eikon: ID:nGNX6Pjh5b
Further company coverage: ANPC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Fresh2
See all newsBrief: Fresh2 Group On Dec 20, Received Nasdaq Notice That It Will Be Delisted From Nasdaq Capital Market Effective At Open Of Market On Dec 24
Brief: Fresh2 Group Ltd. Announces Receipt Of Staff Delisting Determination From Nasdaq Intends To Request A Hearing
Brief: Fresh2 Group Ltd Announces Receipt Of A Delinquency Compliance Alert Notice From Nasdaq
Brief: Anpac Bio-Medical Science - In Dec 2022 And Jan 2023, Signed Definitive Investment Agreements With Several Third Party Investors
Brief: AnPac Bio Granted Continued Listing By Nasdaq Hearing Panel, Subject To Meeting $1 Bid Price Compliance Rule On Or Before Nov. 23, 2022